secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001125345-25-000100
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics Q2 2025 net loss $36.3M; new CEO Eric Risser outlines strategic priorities
--------------------------------------------------------------------------------

- Cash, equivalents and marketables $176.5M as of June 30, 2025; cash runway through first half 2027.
- Total revenue $22.2M ($15.4M contract manufacturing, $6.9M collaboration vs. $10.8M year ago).
- Net loss improved to $36.3M ($0.57/share) from $55.7M ($0.89/share) in Q2 2024.
- Eric Risser named President and CEO, succeeding Scott Koenig who stepped down after 24 years.
- Received $70M upfront from Sagard Healthcare for ZYNYZ royalty purchase agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534525000100/0001125345-25-000100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534525000100/mgnx-20250814.htm
  HTML page:      https://secwatch.observer/filing/0001125345-25-000100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer